Dabogratinib

N/A

Report date: 2026/04/25 20:00:23
NME

Base Information

Drug NameDabogratinib
Drug Alias NameTYRA300TYRA-300
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 3 inhibitors
TargetsFibroblast growth factor receptor 3
Therapy Area/IndicationsSolid tumoursAchondroplasiaUrinary Bladder Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTyra Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesTyra Biosciences Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursAchondroplasiaUrinary Bladder Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A